iiinova — where your digital self keeps evolving

Chad Pecot, MD

@chadpecot.bsky.social

Cancer Killer | Engineering RNA medicines to End Cancer | Potentially sarcastic | Honey-badger

Chad Pecot, MD @chadpecot.bsky.social · 26/06/2025

Now in @Cancer_Cell our group reports the development of a first-in-class EGFR-directed KRAS G12V selective inhibitor. We address two major challenges with RNAi therapeutics in cancer: 1) Delivery, delivery, delivery 2) Achieving mutant selectivity www.cell.com/cancer-cell/... (1/11)

130

Reposted by Chad Pecot, MD

Cancer Cell @cp-cancercell.bsky.social · 19/06/2025

Online Now: A first-in-class EGFR-directed KRAS G12V selective inhibitor

dlvr.it

A first-in-class EGFR-directed KRAS G12V selective inhibitor

Despite KRAS G12V being a common mutation in cancer, no direct inhibitors currently exist. Stanland et al. demonstrate that an EGFR-directed RNAi platform, EFTX-G12V, selectively targets KRAS G12V while sparing wild-type KRAS. EFTX-G12V shows significant anti-tumor effects and provides insights into mutant-selective KRAS targeting and improved therapeutic activity.

041